Skip to content

Prices inUSD

Cart0

Semax vs Selank: Two Pro-Gly-Pro Heptapeptides Compared (2026)

Semax vs Selank: Two Pro-Gly-Pro Heptapeptides Compared (2026)

Semax and Selank turn up together more often than almost any other pair of research peptides. Both are seven amino acids long, both came out of Russian peptide laboratories, and both end in the same three residues. Their first four residues come from completely different parent peptides, though, and that’s where the comparison gets interesting. This guide covers structure, the receptor and assay literature, what kind of studies exist, US status as of October 2026, and how to check a batch.

What’s the difference between Semax and Selank?

Both are synthetic heptapeptides ending in Pro-Gly-Pro. Semax (Met-Glu-His-Phe-Pro-Gly-Pro) borrows its front half from ACTH and appears in BDNF and TrkB expression studies. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) borrows its front half from tuftsin and appears in enkephalinase-inhibition, GABA-receptor and gene-expression studies.

✓ Same length and C-terminal tail; different parent peptides

✓ Different enzyme and receptor systems in the literature

✓ Neither is FDA-approved; Cellugenix supplies both as lab reagents

Semax vs Selank at a Glance

Semax and Selank match in length and in their last three residues, and differ in almost everything else: parent peptide, net charge, mass, and the systems they’re studied in. Identifiers below come from FDA’s substance registry (GSRS) and the FDA’s July 2026 briefing on Semax. You can check each lot against the Semax batch COA and the Selank batch COA.

FieldSemaxSelank
Length7 residues7 residues
SequenceMet-Glu-His-Phe-Pro-Gly-ProThr-Lys-Pro-Arg-Pro-Gly-Pro
Parent peptideACTH(4-7), from the ACTH(4-10) analogue seriesTuftsin (Thr-Lys-Pro-Arg)
Shared featurePro-Gly-Pro C-terminusPro-Gly-Pro C-terminus
Net charge near pH 7About −1About +2
Average MW813.9 g/mol751.9 g/mol
Systems studiedBDNF/TrkB expression; specific binding sites; GABA-receptor systemEnkephalin-degrading enzymes; GABA-receptor system; gene-expression panels
Main study typesCell, rodent, Russian clinical literatureCell, rodent, Russian clinical literature
OriginInstitute of Molecular Genetics, Russian Academy of SciencesRussian research groups, built on tuftsin
US statusNot FDA-approvedNot FDA-approved

The charge row is the one most comparisons skip. Semax carries an acidic glutamate, while Selank carries a basic lysine and arginine, so the two behave differently on ion-exchange columns and in any binding buffer sensitive to charge.

What Is Semax?

Semax is a synthetic heptapeptide that joins Met-Glu-His-Phe, residues 4 to 7 of adrenocorticotropic hormone (ACTH), to a Pro-Gly-Pro tail. FDA’s July 2026 briefing document describes it as a synthetic analogue of the ACTH(4-10) fragment that is “devoid of the hormonal corticotropic and melanotropic properties” of the parent hormone. In receptor terms, that means none of ACTH’s MC2R-driven corticotropic activity.

The sequence explains why. ACTH(4-10) reads Met-Glu-His-Phe-Arg-Trp-Gly, and its His-Phe-Arg-Trp stretch is the core that melanocortin receptors recognise. Semax keeps Met-Glu-His-Phe and replaces Arg-Trp-Gly with Pro-Gly-Pro, so half of that core is gone. For assay design, that points away from melanocortin-receptor panels: Semax’s literature centres on expression and binding work, and a receptor-panel study would be testing an unusual hypothesis.

According to the same FDA document, the Semax used in published work was synthesized at the Laboratory of Regulatory Peptides, Institute of Molecular Genetics, Russian Academy of Sciences. Russian papers on its stability were appearing by 1991.

At the molecular level, the literature measures three kinds of things:

  • Neurotrophin expression. BDNF and TrkB mRNA or protein, measured by qPCR or immunoassay. Shadrina and colleagues (2001) measured neurotrophin mRNAs in cultured rat glial cells.
  • Specific binding. Dolotov and colleagues (2006) reported specific binding of Semax in rat tissue preparations.
  • Transcriptome panels. Genome-wide expression profiling in rodent tissue, mostly from the same Moscow groups.

What Is Semax Peptide?

Semax peptide is the heptapeptide MEHFPGP, C37H51N9O10S, supplied by research vendors as a lyophilized reagent. Structurally, it’s a short ACTH fragment with a stabilising tripeptide tail. The free base has CAS 80714-61-0 and FDA UNII I5FAL2585H; FDA lists a separate CAS, 2828433-33-4, for the acetate salt. Cellugenix lists it with its Semax 10 mg specification and COA.

Is N-Acetyl Semax the Same as Semax?

No. N-acetyl Semax carries an acetyl group on the N-terminal methionine, which adds 42 Da and gives a different molecule with a different expected mass. A certificate for one doesn’t verify the other.

What Is Selank?

Selank is a synthetic heptapeptide that joins tuftsin, the naturally occurring tetrapeptide Thr-Lys-Pro-Arg released from the Fc region of immunoglobulin G, to the same Pro-Gly-Pro tail Semax uses. It’s C33H57N11O9, average MW 751.9 g/mol, CAS 129954-34-3, FDA UNII TS9JR8EP1G.

Most Selank research comes from Russian laboratories, and three assay families dominate:

  • Enzyme kinetics. Inhibition of enkephalin-degrading enzymes, measured with labelled Leu-enkephalin as substrate. Zozulya and colleagues (2001) reported this inhibition, and a 2004 follow-up used tritium-labelled Leu-enkephalin with human plasma enzymes.
  • GABA-receptor binding. Radioligand studies of Selank’s interaction with the GABA-A receptor system, summarised by Vyunova and colleagues (2018).
  • Gene-expression panels. qPCR panels of genes involved in GABAergic signalling, both in rodent tissue (Volkova et al., 2016) and in the IMR-32 cell line (Filatova et al., 2017).

What Is Selank Peptide?

Selank peptide is the heptapeptide TKPRPGP, a tuftsin analogue extended with Pro-Gly-Pro, supplied for laboratory work as a lyophilized solid. It’s basic, carrying two positive side chains, and it contains no sulfur, which makes it easy to tell from Semax by formula alone. See the Selank 5 mg specification and COA.

Watch the name on the label. FDA’s registry lists N-acetyl Selank (UNII J3PM702O93) and Selank diacetate (UNII Q94Z9E92UU) as substances separate from Selank itself. The acetylated form is 42 Da heavier, and the diacetate carries two acetate counter-ions, so each needs its own certificate.

What Is the Difference Between Semax and Selank?

Semax and Selank share their length, their country of origin and a C-terminal tail. They differ in parent peptide, sequence, charge, mass and the systems they’re studied against, so they aren’t interchangeable reagents. Five contrasts carry most of the weight:

  • Parent peptide. Semax starts from a fragment of ACTH, a melanocortin hormone. Selank starts from tuftsin, a fragment of an antibody’s constant region.
  • Sequence and charge. Semax’s Glu makes it slightly acidic overall, at about −1 near pH 7. Selank’s Lys and Arg make it basic, at about +2.
  • Mass and formula. Semax is 813.9 g/mol and contains sulfur in its methionine. Selank is 751.9 g/mol and contains no sulfur. That 62 Da gap makes mass the fastest identity check.
  • Chromatography. Semax carries two aromatic residues, His and Phe, and a hydrophobic Met, so it retains longer on a C18 column and absorbs more strongly in the UV. Selank has no aromatic residues and is strongly basic, so it elutes early and is read mainly at 210 to 220 nm.
  • Systems studied. Semax research centres on neurotrophin expression and binding sites. Selank research centres on enkephalin-degrading enzymes and the GABA-receptor system.

“Which is better?” has no lab answer, because they answer different questions. A study on neurotrophin gene expression and a study on peptidase kinetics simply call for different reagents.

Why Do Semax and Selank Both End in Pro-Gly-Pro?

The Pro-Gly-Pro tail was added to both short parent peptides to slow breakdown by peptidases. FDA’s Semax briefing puts it plainly: the tail “is thought to increase the heptapeptide stability to hydrolysis catalyzed by peptidases,” citing Potaman and colleagues (1991). That study followed the N-terminal degradation of ACTH(4-10) and Semax by rat blood enzymes in vitro.

The logic is the same for Selank. Tuftsin and ACTH(4-7) are each four residues long and are cut quickly by peptidases. Adding a proline-rich tail gives the enzymes a harder target, since proline’s ring makes the peptide bonds around it awkward to cleave. Pro-Gly-Pro is also a known tripeptide in its own right, one of the “glyproline” family that turns up in collagen breakdown.

Treat this as an in vitro stability property. It describes how long a peptide survives in a test tube with enzymes, and nothing more. The tail adds about 251 Da to each parent, which is why both peptides land in the 750 to 815 g/mol range.

Semax and Selank sequences aligned, showing the shared Pro-Gly-Pro C-terminus

Semax and Selank sequences aligned, showing the shared Pro-Gly-Pro C-terminus

What Does the Literature Cover for Semax and Selank?

Most published work on both peptides is Russian-language cell and rodent research, plus Russian clinical literature. Independently replicated English-language data are limited. FDA’s 2026 review of Semax noted that many of the clinical articles it found were published in Russian, some with English abstracts only.

PeptideCell and in-vitroAnimalHuman
SemaxNeurotrophin mRNA in cultured cells; peptidase stabilityRodent gene-expression and BDNF/TrkB studies; binding studiesRussian clinical literature (indications not covered here)
SelankEnzyme-inhibition assays; IMR-32 gene-expression panelsRodent gene-expression and GABA-receptor studiesRussian clinical literature (indications not covered here)

Direct head-to-head work is scarce. One 2020 study (PMID 32342318) examined both peptides using functional-connectivity imaging, a human study type outside this page’s scope. A 2023 binding study by Vyunova and colleagues looked at synthetic ACTH-derived peptides and the GABA-receptor system, one of the few places the two literatures overlap.

Much of the English-language record appears in translated Russian journals, such as Bulletin of Experimental Biology and Medicine and Doklady Biological Sciences. These run short, often two or three pages, with methods compressed to a paragraph. Reproducing an assay from one usually means tracking down the original Russian paper or the group’s earlier methods work.

Three cautions apply when reading these papers:

  • Small studies. Many use small groups and a single laboratory.
  • Narrow authorship. A handful of Moscow institutes produced most of the work, so outside replication is thin.
  • Language. Full methods are often in Russian, which makes protocols hard to check.

Why Are Semax and Selank Studied Side by Side?

They make natural comparators. Each is a four-residue parent peptide with the same stabilising tail, so running both in one experiment helps separate what the tail does from what the parent sequence does. Published combination studies are very limited.

A clean side-by-side design keeps each peptide in its own arm. It adds a vehicle control and a tail-only control, Pro-Gly-Pro itself, and matches each readout to the target: enzyme kinetics for Selank’s peptidase work, expression assays for Semax’s neurotrophin work. Running a single readout for both tends to flatter whichever peptide that assay was built around.

Concentrations deserve a second look too. Because Selank is about 8% lighter, one milligram holds 1.33 µmol of Selank against 1.23 µmol of Semax. Preparing both at the same mg/mL quietly puts more moles of Selank than Semax in every well, so set stocks by molarity.

Are Semax and Selank FDA-Approved? US and International Status

Neither Semax nor Selank is FDA-approved for any use in the US. Drugs@FDA lists no application for either as of October 14, 2026. Research-grade Semax and Selank are sold as laboratory reagents, and they aren’t medicines.

ItemSemaxSelank
Drugs@FDANo applicationNo application
FDA PCAC review, July 2026Evaluated; FDA staff proposed against the 503A Bulks ListNot reviewed
503A interim category list (May 14, 2026)Not listedNot listed
21 CFR 216.23 (codified 503A list)Not listedNot listed

FDA’s Semax briefing document for the July 23-24, 2026 advisory committee meeting concludes that the criteria “weigh against placing both semax (free base) and semax acetate” on the 503A Bulks List. Committee votes are advisory, and no final FDA action on Semax has been published as of October 14, 2026.

Outside the US, the same FDA document notes that Semax is a registered drug in Russia. Status elsewhere, including the UK, Canada, and the EU, varies by country and changes often, so check the national regulator before relying on any summary. For the supply side there is research peptides in the USA, and the label wording is what research use only means.

How to Verify Research-Grade Semax and Selank

The batch certificate is the place to start. Because the two expected masses differ by about 62 Da, a mass result tells them apart at a glance, and HPLC purity covers the rest. The fact sheet below lists what each certificate should match.

FieldSemaxSelank
SequenceMEHFPGPTKPRPGP
FormulaC37H51N9O10SC33H57N11O9
Average MW813.9 g/mol751.9 g/mol
Expected [M+H]+814.36752.44
CAS80714-61-0129954-34-3
Purity by HPLCSee the batch COASee the batch COA
Identity cards for Semax and Selank listing sequence, formula, average molecular weight, expected protonated (M+H) ion, CAS, FDA UNII, PubChem CID, and net charge

Identity cards for Semax and Selank listing sequence, formula, average molecular weight, expected protonated (M+H) ion, CAS, FDA UNII, PubChem CID, and net charge

Short fragments are the impurities to watch for. A truncated or partly hydrolysed sample can show the parent tetrapeptides, tuftsin (Thr-Lys-Pro-Arg, about 500.6 g/mol) or Met-Glu-His-Phe (about 562.6 g/mol), or the free Pro-Gly-Pro tail (about 269.3 g/mol). On an HPLC trace, these small, polar pieces usually elute well before the full heptapeptide.

When you read a certificate, check four things:

  1. The lot or report number matches the vial.
  2. The HPLC method and result are both shown, with the chromatogram.
  3. Any mass result matches the fact sheet above.
  4. The testing laboratory and the test date are named.

Our current certificates are HPLC-UV purity and content reports from Testides: Semax 10 mg, report LK-SEM-10-012926, and Selank 5 mg, report LK-SEL-5-021126. Purity by HPLC: see each batch result. Neither report includes a mass result, so identity on these lots rests on HPLC. Our guides cover how to read a peptide COA and the trade-offs of HPLC vs mass spectrometry.

How Should Sealed Vials Be Stored?

Keep both peptides lyophilized, sealed, cold, dry and dark, as stated on each label. Semax’s methionine is the more oxidation-prone residue of the two, so it’s the one to keep most carefully away from light and air. Our lyophilized peptide storage guide lists temperature ranges.

Frequently Asked Questions

What is the molecular weight of Semax?

Semax (C37H51N9O10S) has an average molecular weight of 813.9 g/mol and a monoisotopic mass of 813.35 Da, so its expected [M+H]+ ion is about 814.36. Its CAS number is 80714-61-0 for the free base. FDA lists the acetate salt separately, as C39H55N9O12S at 874.0 g/mol.

What is the molecular weight of Selank?

Selank (C33H57N11O9) has an average molecular weight of 751.9 g/mol and a monoisotopic mass of 751.43 Da, so its expected [M+H]+ ion is about 752.44. Its CAS number is 129954-34-3. It contains no sulfur, unlike Semax, and salt forms such as the diacetate weigh more.

Is Selank derived from tuftsin?

Yes. Selank’s first four residues, Thr-Lys-Pro-Arg, are tuftsin, a tetrapeptide released from the Fc region of immunoglobulin G. Selank adds Pro-Gly-Pro to that sequence, giving a seven-residue peptide. The tail was added to slow peptidase breakdown, the same design used in Semax.

What is the difference between Semax and NAD+?

They belong to different chemical classes. Semax is a seven-residue peptide, Met-Glu-His-Phe-Pro-Gly-Pro, with a molecular weight of 813.9 g/mol. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme built from two nucleotides, used in enzyme assays as an electron carrier. They’re checked with different methods and share no structure.

Does Cellugenix publish COAs for Semax and Selank?

Yes. Every lot links to a certificate whose report number verifies on the testing lab’s own archive: LK-SEM-10-012926 for Semax 10 mg and LK-SEL-5-021126 for Selank 5 mg, both tested by Testides with HPLC-UV. Purity by HPLC: see each batch result in the COA library.

The Bottom Line

Semax and Selank are two heptapeptides with the same Pro-Gly-Pro tail and different parents: an ACTH fragment and tuftsin. That gives them different charges, masses and target systems, so they aren’t interchangeable. Neither is FDA-approved, and Cellugenix supplies both as laboratory reagents with batch certificates. Browse Cellugenix’s neuropeptide research compounds.

For laboratory research use only. Not for human or animal use. Products are supplied to qualified purchasers under our Terms of Service.

Sources

  • FDA. Briefing document, semax-related bulk drug substances, Pharmacy Compounding Advisory Committee, July 23-24, 2026.
  • FDA. Global Substance Registration System: Semax (I5FAL2585H), Selank (TS9JR8EP1G).
  • FDA. Drugs@FDA, searched October 14, 2026; Bulk Drug Substances Nominated for Use in Compounding Under Section 503A, updated May 14, 2026; eCFR 21 CFR 216.23.
  • PubChem. Semax, CID 9811102; Selank, CID 11765600.
  • Potaman VN, Alfeeva LY, et al. Biochemical and Biophysical Research Communications, 1991; 176(2): 741-746. PMID 1851003.
  • Shadrina MI, Dolotov OV, et al. Neuroscience Letters, 2001; 308(2): 115-118. PMID 11457573.
  • Dolotov OV, Karpenko EA, et al. Journal of Neurochemistry, 2006; 97 Suppl 1: 82-86. PMID 16635254.
  • Zozulya AA, Kost NV, et al. Bulletin of Experimental Biology and Medicine, 2001; 131(4): 315-317. PMID 11550013.
  • Zolotarev YuA, Sokolov OYu, et al. Bioorganicheskaya Khimiya, 2004; 30(3): 234-240. PMID 15344652.
  • Vyunova TV, Andreeva L, et al. Protein & Peptide Letters, 2018; 25(10): 914-923. PMID 30255741.
  • Volkova A, Shadrina M, et al. Frontiers in Pharmacology, 2016; 7: 31. PMID 26924987.
  • Filatova E, Kasian A, et al. Frontiers in Pharmacology, 2017; 8: 89. PMID 28293190.
  • Vyunova TV, Andreeva LA, et al. Chemical Biology & Drug Design, 2023; 101(6): 1393-1405. PMID 36828803.
  • Panikratova YR, Lebedeva IS, et al. Doklady Biological Sciences, 2020; 490(1): 9-11. PMID 32342318.
  • Testides. Reports LK-SEM-10-012926 and LK-SEL-5-021126.

For laboratory research use only. Not for human or animal use.

0